Vinorelbine plus cisplatin vs Paclitaxel plus cisplatin in treatment of patients with advanced non-small-cell lung cancer

Objective:To compare the efficacy and toxicity of vinorelbine plus cisplatin(NP)and paclitaxel plus cisplatin(TP)combinations in the treatment of advanced non-small-cell lung cancer(NSCLC).Methods:61patients with advanced NSCLC were randomized to receive vinorelbine 25mg/m~2 on the 1stand 8th day by infusion and cisplatin 20mg/m~2 from the 1st to the 5th day(group NP,30 patients),or paclitaxel 135mg/m~2 on the 1st day by infusion and cisplatin 20mg/m~2 for 3~4 hours from the 2nd to 6th day(group TP,31 patients).Both regimens were repeated every 3 weeks.Results:Objective response rate of 40.0% was observed in NP group versus 45.2% in TP group(P0.05).The 1-year survival rate was 36.7% in NP group and 41.9% in TP group(P0.05).The median survival duration was 10.7 months in NP group and 10.2 months in TP group.Myelosuppression was major dose-limiting toxicity.The incidence of neutropenia were 86.7% in NP group,and 67.7% in TP group.Phlebitis and nausea/vomiting were more severe in NP groug.By contrast,alopecia and peripheral neutrotoxicity/myalgia were more frequent in TP roup.Conclusion:The NP combination is as equally active and well tolerated as the TP combination in patients with advanced non-small-cell lung cancer.